Bioarctic gör flera tunga rekryteringar: "Tid att växla upp"

Bioarctic, som utvecklar en behandling mot Alzheimers sjukdom, gör flera rekryteringar inför en kommande ansökan om marknadsgodkännande. – Bioarctic tar nu det ...

Trends and overview: ELRIG "Robotics and Automation"

Laboratories on the way to end-to-end automation: Robotics, artificial intelligence and automation technology boosted by pandemic

Karolinska i Europatopp när "smartaste" sjukhusen rankas

Karolinska universitetssjukhuset i Solna är bäst i Europa på att använda ny teknik inom sjukvården, enligt en rankning i tidskriften Newsweek.

Hon tar plats på Bactiguard

Petra Kaur Ljungman tillträder den nyinrättade rollen som global marknads- och kommunikationschef.

Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”

It´s like a scientist’s dream: to be the world’s first with a drug that genuinely affects one of our major diseases. Lars Lannfelt and his company Bioarctic hav...

Marie Gårdmark: New incentives for orphan products on its way

"Let’s hope that the learnings from development of new therapies for rare diseases will spill over to more common conditions, orphan products paving the wave fo...

Samuel Lagercrantz: Immunotherapy against cancer is still in its early stages

with the saying: He who laughs last laughs best, writes Samuel Lagercrantz in an editorial.

A smart company takes care of its best

Lundbeck didn't have to look far to find it's new international Director of Marketing. The talent was already in the house.

The stomach medication that became the biggest blockbuster of the 1990s

The omeprazole molecule was synthesised as early as 1979, but it took many years before the then Astra had an approved pharmaceutical. Once this happened, a tab...

Hello Angelica Loskog!

Life Science Sweden would like to know more about Angelica Loskog and interviews her about her life as a researcher.

Nordic Regulatory experts: Improving biotech chances of Succ

Why is it that so many biotech companies fail? And what are the tools needed to change that fact?

Giulia Gaudenzi: Innovation for good

"I challenge the innovator landscape to take a mental leap. Relying on innovation-solely to end inequality is not enough, therefore consciously and purposively ...

Bought a tablet factory – and built his own empire

In 1995, Thomas Eldered was CEO of one of Pharmacia’s factories in the Stockholm area when the Swedish pharmaceutical giant, after a takeover, decided to move i...

Pilots want to live too

Bactiguard stärker upp operations

Rekryterar VP direkt från Pfizer.

Genovis i kontrakt med megabolag

Ska utveckla analys av biologiska läkemedel.

Saving lives worldwide with low-cost molecular diagnostics

High throughput testing for many upper respiratory tract pathogens thanks to automation technology

Första behandlingen mot ebola på väg

CHMP rekommenderar godkännande av vaccinet Ervebo för förebyggande behandling mot ebolainfektion.

Nytt partnerskap för Bactiguard

Bolaget ingår partnerskap med en schweizisk distributör som kommer att hantera hela Bactiguards infektionsförbyggande portfölj.

Alligators kandidat visar kraftfull effekt

Lundabaserade Alligator bioscience kandidat ATOR-1017 mot spridd cancer visar kraftfulla anti-tumöreffekter. Bolaget siktar på att starta studier i cancerpatienter senare i år.

Biosimilars bring price pressure, but are they sufficiently used?

When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely e...

Column: Repurposing as a golden ticket to approval

"Hopefully, in the end, patients will be winners by receiving on-label treatments for which benefit-risk has been properly assessed." In a column Marie Gårdmark...

Column: Why there cannot be a complete cure for cancer – but there is certainly another way!

"Is there a new way we need to be thinking about how to prevent cancer?" Lucy Robertshaw reflects upon which is the smartest way to beat cancer.

CAR-T therapies give continued hope: “Almost half of the patients have become disease-free”

become disease-free, at least of those treated with Yescarta, which are the ones I know best,” says Gunilla Enblad, Chairman of the national working group for CAR-T treatment.